Epidemiology, prognostication and treatment outcome of gastrointestinal stromal tumour: A single centre prospective study

Introduction and Aim: GI stromal tumours (GISTs) being most frequent mesenchymal of the alimentary tract have few studies on epidemiology in this subcontinent. The current prospective study is aimed at gathering data molecular possible effect markers standard pathological prognostic factors also to measure overall disease outcome.
 
 Materials Methods: In epidemiologic conducted from 2016 2019, all GIST patients registering Radiotherapy Department IPGME & R, Kolkata, India; identified by histopathology were prescribed pre-specified immune-histochemical tests offered a protocolized treatment. followed up for minimum twelve months average thirty months, watch progression.
 Results: A total 38 with median age 49.5 years male predominance (p= 0.005) presented commonly abdominal pain (42.1%); jejunum (31.6%) stomach (26.3%) common sites, spindle cell type (78.9%) commonest histological type. Immunohistochemistry showed positive expression SMA (7.9%), DOG1 (28.9%), CD34 (31.6%), CD117/cKIT (65.8%). CD117 positivity (Rho= -0.366, p=0.024) has negative association mitotic count, whereas (Rho=.513, p=0.001) (Rho=.459, p=0.004) tumour dimension. was found be contributing factor progression (RR 12.57, p=0.035).
 Conclusion: sub-continental patients, gender distribution GISTs differ western countries but not features. Molecular important significance.